
Opinion|Videos|March 14, 2025
CGM's Impact on Clinical Inertia
This program was supported through an independent medical education grant from Dexcom Medical Affairs. Experts discuss how continuous glucose monitoring (CGM) adoption impacts clinical inertia and supports earlier therapeutic interventions across different patient populations, highlighting measurable improvements in patient outcomes, such as glycemic control, hemoglobin A1c (HbA1c) levels, hypoglycemic events, and quality of life.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How does CGM adoption impact clinical inertia and support earlier therapeutic interventions across different patient populations?
- What measurable improvements have been seen with CGMs in patient outcomes (eg, glycemic control, HbA1c levels, hypoglycemic events, quality of life)?
- Because each segment is considered a separate entity, each group of discussion questions should reset with No. 1 if using numbers.
Advertisement
Related to this article

A scoping review of 15 studies found psoriasis prevalence markedly lower across 13 indigenous populations worldwide.

MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, found.

This week in health equity and access: PMOS diagnosis, HIV lung cancer screening, transplant access, atopic dermatitis care, and value-based oncology.

Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.

Among people with HIV, lung cancer screening eligibility rose from 6% to 15% in 6 years, but uptake stayed under 30%.

New data on atopic dermatitis show treatment gaps, heavy reliance on dermatology APPs, and wide state variation in specialist supply

Sustainable models require asking what a result shows, what design produced it, and whether the design was built to measure value or just produce a number.
Advertisement
Advertisement
Trending on AJMC
1
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
2
Systemic Sclerosis Linked to Dramatic Rise in Lung Cancer Risk
3
VBC Risk Is Outpacing Provider Readiness, CMS Must Act
4
FDA Approves First Heart Valve to Keep Pace With Children's Growth
5


